Recent Updates
Recently added Catalysts
URGN Positive Sentiment

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

Wednesday, July 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: UroGen Pharma Ltd. has announced the receipt of a Notice of Allowance for a new U.S. patent. This patent is expected to provide protection for its products ZUSDURI™ and UGN-103 until July 2044. The new patent is anticipated to strengthen UroGen's market position in the treatment of urothelial and specialty cancers.
Price reaction · baseline $39.19 (2026-07-14 close) · hit pre-market · clean, no other URGN news in the window
day 0 close · peak
+1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • UroGen receives a new U.S. patent allowance.
  • Patent protection extends to July 2044.
  • This is expected to enhance the market position of ZUSDURI™ and UGN-103.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+188%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
UGN-104
Phase 3 · Upper Urinary Tract Urothelial Carcinoma

Full Press Release Details

PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has received a Notice of Allowance from the U.S.

Frequently Asked Questions

What is the significance of UroGen's new patent allowance?

The new patent allowance provides UroGen protection for ZUSDURI™ and UGN-103 until July 2044.

How long is the patent protection for UroGen's products?

The patent protection extends until July 2044.

Which products are covered by the new U.S. patent?

The patent covers UroGen's ZUSDURI™ and UGN-103.

What type of cancers does UroGen focus on?

UroGen focuses on treating urothelial and specialty cancers.

ShareAdd on Google
Tags: URGN Viatris Investor Conferences Healthcare UroGen ZUSDURI UGN-103 U.S. patent biotech
Last updated: Jul 15, 2026

Biotech snapshot

Cash runway
$109M liquidity · $11M/mo burn
~9 mo
Medium dilution risk
Lead asset
UGN-104Phase 3
Upper Urinary Tract Urothelial Carcinoma →

Catalyst track record

+188%
best trade around URGN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for URGN.

See every catalyst's timing & PoA →